Skip to main content

Table 1 General characteristics of patients

From: Pharmacokinetics of piperacillin/tazobactam in cancer patients with hematological malignancies and febrile neutropenia after chemotherapy

Parameter Number (%)
Age (years)  
 18– 24 7 (50.0)
 25 - 31 3 (21,4)
 40 - 60 4 (28.6)
Sex  
 Female 8 (57.1)
 Male 6 (42.9)
Weight (kg)  
 40 - 50 5 (35.7)
 51 – 60 6 (42.9)
 61 - 80 3 (21.4)
 Mean ± SD = 56.4 ± 11.2  
Height (cm)  
 150 – 160 9 (64.3)
 161 – 170 4 (28.6)
 171 – 180 1 ( 7.1)
BMI kg/m 2  
 17.0 – 22.0 8 (57.2)
 22.1 – 27.0 5 (35.7)
 27.1 – 32.0 1 (7.1)
 Mean ± SD = 21.9 ± 4.0  
Creatinine clearance (mg/mL)  
 80 - 110 3 (21.4)
 111 - 140 6 (42.9)
 141 - 170 5 (35.7)
Albumin g/dL  
 2.0 – 2.6 3 (21.4)
 2.7 – 3.3 7 (50.0)
 3.4 – 4.0 4 (28.6)
 Mean ± SD = 3.0 ± 0.6  
Antibiotic given in the previous month?  
 Yes 5 (35.7)
 No 9 (64.3)
Malignancy  
 Lymphoma 2 (14.3)
 Lymphoid leukemia 9 (64.3)
 Myeloid leukemia 3 (21.4)
Number of neutrophils/mm 3  
 Range 0–2380
 Mean ± SD 208(603.2)
Therapy cycles  
 1 – 2 6 (42.9)
 3 – 5 3(21.4)
 6 - 8 5 (35.7)
FN-associated chemotherapy  
 Hyper-CVAD 10 (71.4)
 No Hyper-CVAD 4 (28.6)
  1. BMI, body mass index; FN, febrile neutropenia; GFR, glomerular filtration rate.
  2. For Hyper-CVAD chemotherapy, course A comprised cyclophosphamide, vincristine, doxorubicin and dexamethasone, and course B consisted of methotrexate and cytarabine.
  3. Mentioned on page 6.